东北制药： 创新突围多元布局促转型升级

Core Viewpoint - Northeast Pharmaceutical is currently in a critical period of deep adjustment and transformation in the pharmaceutical industry, emphasizing the importance of each step in its development [1] Group 1: R&D and Strategic Transformation - Northeast Pharmaceutical is a significant drug production and export base in China, focusing on innovation-driven strategies and core business enhancement, achieving important results in R&D breakthroughs and quality improvement [2] - The company has increased R&D investment, aiming to accelerate the transition of innovative results from the laboratory to clinical applications [2] - The DCTY0801 injection, developed by its subsidiary, is set to undergo clinical trials for specific types of high-grade brain gliomas, marking a substantial breakthrough in cancer treatment innovation [2] - The acquisition of a 70% stake in DCTY0801's developer allows Northeast Pharmaceutical to quickly enter the cell therapy field, positioning it as a key platform for innovative drug development [3] - The company is committed to building a systematic and scalable talent cultivation system to enhance its R&D capabilities and facilitate its strategic shift from chemical pharmaceuticals to biological innovative drugs [3] Group 2: Quality Assurance and Market Expansion - Strong R&D capabilities provide essential support for product quality enhancement, which is crucial for global market competition [4] - The company’s core raw material product, Phosphomycin Amide, received the European Pharmacopoeia suitability certificate (CEP) in 2025, becoming the first domestic company to achieve this certification, enhancing its brand image and competitiveness in the international high-end market [4] - Northeast Pharmaceutical successfully passed a surprise inspection by the FDA, demonstrating its leading quality control system across the entire production and management chain [4] - The company is enhancing its quality management capabilities to support its expansion in both domestic and international markets [4] Group 3: Business Diversification and Value Enhancement - Northeast Pharmaceutical is expanding into related business areas, developing health food products based on the concept of "medicinal food homology" and launching a skincare brand, "Qifangyuan," to enter the beauty market [6] - The company’s diversification efforts are based on professional technology and aim to extend the value chain around the core of "health" [6] - The "Qifangyuan" brand integrates pharmaceutical technology and standards into skincare product development, showcasing the company's innovative approach [6] - Northeast Pharmaceutical is committed to optimizing its health product matrix and exploring comprehensive health services to create additional growth points [6] Group 4: Recognition and Achievements - The company’s improved business layout and solid operational results have enhanced its overall strength, leading to recognition from various sectors [7] - In 2025, Northeast Pharmaceutical was included in the list of recommended "National Intellectual Property Demonstration Enterprises" in Liaoning Province and re-certified as a national high-tech enterprise [7] - The company received the title of "Top 100 Pharmaceutical Industrial Enterprises by Revenue" for the 2024-2025 period in industry evaluations [7]